Is Chagas cardiomyopathy an independent risk factor for patients with heart failure?

Some studies showed increased mortality in chagasic patients but most of these studies did not perform statistical adjustments to socioeconomic variables. The main objective of this study was to investigate if there is an independent association between Chagas etiology and mortality in patients with heart failure and moderate to severe left ventricle systolic dysfunction. Stratified analysis by the variables associated to chagasic etiology and multivariate analysis through logistic regression were performed to evaluate the relationship between Chagas cardiomyopathy and one-year mortality. Among 417 patients initially evaluated, 191 had the inclusion criteria. The mortality was higher in patients with Chagas cardiomyopathy than in the patients with other etiologies (log rank test; p=0.036). At one-year follow-up, the mortality in chagasic patients was 21.6% versus 10.6% in the remaining (relative risk=2.03; 95% CI=0.98-4.2; p=0.05). At logistic regression, educational level was identified as a confounder variable of the association between Chagas cardiomyopathy and one-year mortality. This association was no more statistically significant after adjustment for educational level (odds ratio=1.67; 95% CI=0.63-4.41). In this study, Chagas cardiomyopathy was a marker of worse prognosis, but was not independently associated to increased one-year mortality in outpatients with heart failure and moderate to severe systolic dysfunction.

Influence of gender on the prognostic value of troponin I after elective percutaneous coronary interventions.

OBJECTIVE: To evaluate the association between troponin I concentrations (TnI) in patients submitted to elective percutaneous coronary interventions (PCI) and adverse coronary events (ACE) during a six month follow-up period. METHODS: One hundred and eleven patients who had been submitted to an elective PCI were consecutively selected during a one year timeframe. The patients had stable angina (SA), unstable angina (UA) or silent ischemia (SI) and were asymptomatic for at least 72 hours before the procedure. TnI concentrations were measured between 8 and 24 hours after the PCI. Each patient was contacted by telephone six months later and interviewed regarding ACE which were defined as death, myocardial infarction, new revascularization and recurrent ischemia. RESULTS: Twenty-four patients showed elevated concentrations of TnI (21.6%) after the PCI regardless of clinical characteristics or procedure complications. Those who presented elevated TnI concentrations had higher event rates: 66.7 vs. 42.5% (RR=1.57; CI 95%=1.08-2.28). This risk seems to be higher in the subgroups of females and patients with a previous diagnosis of unstable angina. Multivariate analysis confirmed that gender was the only effect modifying co-variable associated with ACE risk, which is higher for females with elevated TnI concentrations (OR=7.22; CI 95%=1.4 -36.9) and unaltered for males (OR=1.26; CI 95%=0.35-4.55). CONCLUSION: Elevated TnI concentrations were a common occurrence after PCI and is a factor related to the development of ACE in the mid term. However, when adjusted for other variables, this effect is only maintained in female patients.

Influência do gênero no valor prognóstico da troponina I após angioplastia coronariana eletiva / Influence of gender on the prognostic value of troponin I after elective percutaneous coronary interventions

OBJETIVO: Avaliar a associação entre níveis de troponina I (TnI) em pacientes submetidos, eletivamente, a intervenções coronárias percutâneas (ICP) com ocorrência de eventos cardíacos adversos (ECA) no seguimento de 6 meses. MÉTODOS: No período de um ano, foram selecionados consecutivamente 111 pacientes submetidos a ICP eletiva, com angina estável (AE), instável (AI) ou isquemia silenciosa (IS), assintomáticos por mais de 72 horas antes do procedimento. As dosagens de TnI foram realizadas entre 8 e 24 horas após a ICP. Cada paciente foi contatado por telefone, após seis meses, e questionado quanto à ocorrência de ECA, definidos como morte, infarto do miocárdio, nova revascularização e recorrência de isquemia. RESULTADOS: Ocorreu elevação de TnI em 24 (21,6 por cento) pacientes após a ICP, independente de características clínicas e complicações do procedimento. O surgimento de eventos foi mais freqüente em quem apresentou elevação de TnI: 66,7 vs. 42,5 por cento (RR=1,57; IC95 por cento=1,08-2,28). Este risco parece ser maior nos subgrupos de gênero feminino e naqueles com diagnóstico prévio de AI. Após análise multivariada, apenas gênero se confirmou como co-variável modificadora de efeito com risco de ECA maior em mulheres com elevação de TnI (OR=7,22. IC95 por cento=1,4 -36,9) e similar em homens (OR=1,26. IC95 por cento=0,35-4,55). CONCLUSÃO: Elevação de TnI foi freqüentemente encontrada após ICP e é um fator associado ao surgimento de ECA a médio prazo. Entretanto, quando ajustada para outras variáveis, este efeito só se manteve em pacientes do gênero feminino.

OBJECTIVE: To evaluate the association between troponin I concentrations (TnI) in patients submitted to elective percutaneous coronary interventions (PCI) and adverse coronary events (ACE) during a six month follow-up period. METHODS: One hundred and eleven patients who had been submitted to an elective PCI were consecutively selected during a one year timeframe. The patients had stable angina (SA), unstable angina (UA) or silent ischemia (SI) and were asymptomatic for at least 72 hours before the procedure. TnI concentrations were measured between 8 and 24 hours after the PCI. Each patient was contacted by telephone six months later and interviewed regarding ACE which were defined as death, myocardial infarction, new revascularization and recurrent ischemia. RESULTS: Twenty-four patients showed elevated concentrations of TnI (21.6 percent) after the PCI regardless of clinical characteristics or procedure complications. Those who presented elevated TnI concentrations had higher event rates: 66.7 vs. 42.5 percent (RR=1.57; CI 95 percent=1.08-2.28). This risk seems to be higher in the subgroups of females and patients with a previous diagnosis of unstable angina. Multivariate analysis confirmed that gender was the only effect modifying co-variable associated with ACE risk, which is higher for females with elevated TnI concentrations (OR=7.22; CI 95 percent=1.4 -36.9) and unaltered for males (OR=1.26; CI 95 percent=0.35-4.55). CONCLUSION: Elevated TnI concentrations were a common occurrence after PCI and is a factor related to the development of ACE in the mid term. However, when adjusted for other variables, this effect is only maintained in female patients.

[Clinical and therapeutics aspects of heart failure due to Chagas disease]. / Aspectos clínicos e terapêuticos da insuficiência cardíaca por doença de Chagas.

OBJECTIVE: Describe the clinical and therapeutic characteristics of patients with heart failure (HF) secondary to chronic chagasic cardiomyopathy and evaluate if these characteristics are different from those found in other etiologies. METHODS: A prospective analysis of the patients treated between August 2003 and June 2004 at a HF referral outpatient clinic was conducted. RESULTS: Three hundred and fifty six patients diagnosed with HF were included in the study. Chagasic cardiomyopathy was the most common etiology (48% of the cases). Other etiologies included hypertensive cardiomyopathy in 19% of the patients, idiopathic dilated in 11% and ischemic in 9%. Patients with HF secondary to chagasic cardiomyopathy were more frequently from non-white ethnic groups (88 vs. 75%; p = 0.002), had a family history of Chagas disease (57 vs. 21%; p = 0.001), had the disease for a longer length of time (71 vs. 56 months; p = 0.034), had lower levels of education (4.4 +/- 4.1 vs. 5.7 +/- 4.2 years of study; p = 0.004), had a lower heart rate (69 +/- 12 vs. 73 +/- 13; p = 0.03) and a lower systolic blood pressure (121 +/- 25 vs. 129 +/- 28 mmHg; p = 0.006). There was also a higher incidence of the use of amiodarone (22 vs. 13%; p = 0.036) and artificial pacemakers (15 vs. 1%; p = 0.001). There was a lower usage of beta-blockers (39 vs. 59%; p = 0.001). CONCLUSION: In this sample of HF outpatients, in a state with a high prevalence of Chagas disease, chagasic cardiomyopathy was the most common etiology and they presented some unique clinical and therapeutic characteristics in comparison to other heart failure patients.

Aspectos clínicos e terapêuticos da insuficiência cardíaca por doença de Chagas / Clinical and therapeutics aspects of heart failure due to Chagas disease

OBJETIVO: Descrever as características clínicas e terapêuticas de pacientes com insuficiência cardíaca (IC) secundária a miocardiopatia chagásica crônica, bem como avaliar se estas são diferentes nas demais etiologias. MÉTODOS: Foram analisados prospectivamente pacientes atendidos no período de agosto de 2003 a junho de 2004, em um ambulatório de referência para IC. RESULTADOS: Foram incluídos 356 pacientes com o diagnóstico de IC. Miocardiopatia chagásica foi a etiologia mais freqüente, (48 por cento dos casos). Outras etiologias foram miocardiopatia hipertensiva em 19 por cento, dilatada idiopática em 11 por cento, e isquêmica em 9 por cento. Pacientes com IC secundária a miocardiopatia chagásica tinham com maior freqüência etnia não-branca (88 x 75 por cento; p = 0,002), história familiar de doença de Chagas (57 x 21 por cento; p = 0,001), maior tempo de doença (71 x 56 meses; p = 0,034), menor escolaridade (4,4 ± 4,1 x 5,7 ± 4,2 anos de estudo; p = 0,004), menor freqüência cardíaca (69 ± 12 x 73 ± 13; p = 0,03) e pressão arterial sistólica (121 ± 25 x 129 ± 28 mmHg; p = 0,006). Utilizavam com maior freqüência amiodarona (22 x 13 por cento; p = 0,036) marcapassos artificiais (15 x 1 por cento; p = 0,001) e com menor freqüência drogas betabloqueadoras (39 x 59 por cento; p = 0,001). CONCLUSÃO: Nessa amostra de pacientes ambulatoriais com IC, em um estado com alta prevalência de doença de Chagas, miocardiopatia chagásica foi a etiologia mais freqüente, apresentando algumas características clínicas e terapêuticas diferentes dos demais pacientes.

Comparison of an intravenous pulse of methylprednisolone versus oral corticosteroid in severe acute rheumatic carditis: a randomized clinical trial.

OBJECTIVES: To compare the short-term prognosis of patients with severe acute rheumatic carditis when treated with an intravenous pulse of methylprednisolone in comparison with conventional treatment using oral prednisone. METHODS: We designed a randomized clinical trial in the setting of a university general hospital in Brazil. We randomly allocated 18 patients with the diagnosis of severe acute rheumatic carditis and congestive heart failure to receive an intravenous pulse as opposed to oral prednisolone. Methylprednisolone was administered in a dose of 1 g intravenously for 3 consecutive days in the first and second weeks, for two days in the third, and one day in the fourth week. Prednisone was administered in a dose of 1.5 mg/kg/day over the period of 4 weeks. RESULTS: The mean age of the patients was 11.1 +/- 3.7 years, with a median of 12 years. Patients on oral treatment showed a more pronounced decrease in the heart rate, sedimentation rate, and in the titres of C-reactive protein than those receiving intravenous therapy. At the end of treatment, a mild decrease in the left ventricular end-systolic dimension was found in those having oral treatment, compared to an increase in the group having intravenous treatment (p = 0.036). The ejection fraction showed a median increase of 5% in those undergoing oral treatment, and a median decrease of 6% in the group with intravenous therapy (p = 0.009). There were 5 therapeutic failures in those receiving intravenous therapy (56%), including 1 death. Therapeutic failures were not observed in those treated orally (p = 0.03). CONCLUSION: Intravenous treatment of methylprednisolone, as a single anti-inflammatory agent, was inferior to conventional treatment with oral prednisone in the control of severe rheumatic carditis.